Table 2.
Use of S1PR drugs in clinical trial for central nervous system (CNS) disease.
| S1PR drugs in clinical trial | Target | Indication for diseases |
|---|---|---|
| Fingolimod- FTY720 | S1P1–S1P5 | RR-MS |
| Siponimod- BAF312 | S1P1, S1P5 | SP-MS RR-MS |
| Ozanimod- RPC1063 | S1P1 | RR-MS |
| Ceralifimod- ONO-4641 | S1P1, S1P5 | RR-MS |
| GSK2018682 | S1P1 | RR-MS |
| Ponesimod- ACT-128800 | S1P1 | RR-MS |
| KRP203 | S1P1 | Ulcerative colitis Systemic lupus erythematosus |
| Cenerimod- ACT-33441 | S1P1 | Systemic lupus erythematosus |
| Amiselimod- MT1303 | S1P1, S1P4, S1P5 | RR-MS Crohn’s disease Psoriasis |
| Etrasimod- APD334 | S1P1, S1P4, S1P5 | Ulcerative colitis |
RR-MS, relapsing–remitting multiple sclerosis; SP-MS, secondary progressive multiple sclerosis.